GENFF (Genflow Biosciences) Total Receivables: $0.36 Mil (As of Dec. 2025)


What is Genflow Biosciences Total Receivables?

Genflow Biosciences GENFF Total Receivables is $0.36 Mil as of Dec. 2025. The stock has 1 warning sign investors should review.

Genflow Biosciences's Total Receivables for the quarter that ended in Dec. 2025 was $0.36 Mil.

Genflow Biosciences Total Receivables Related Terms

Genflow Biosciences Total Receivables Historical Data

* Premium members only.

The historical data trend for Genflow Biosciences's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genflow Biosciences Total Receivables Chart

Genflow Biosciences Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
0.01 0.12 0.39 0.01 0.36

Genflow Biosciences Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.39 0.00 0.01 0.11 0.36

Genflow Biosciences Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of $0.36 Mil mean?
Genflow Biosciences (GENFF) has a Total Receivables of $0.36 Mil as of Dec. 2025. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Genflow Biosciences and its competitors.
Is Genflow Biosciences' Total Receivables too high?
Genflow Biosciences' current Total Receivables is $0.36 Mil.
How does Genflow Biosciences' Total Receivables compare to VRTX and REGN?
Genflow Biosciences' Total Receivables of $0.36 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Genflow Biosciences and its competitors. Genflow Biosciences's current Total Receivables is $0.36 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genflow Biosciences stock overvalued right now?
Genflow Biosciences (GENFF) has a current Total Receivables of $0.36 Mil. The current Total Receivables is $0.36 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Genflow Biosciences (GENFF), the current Total Receivables is $0.36 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Genflow Biosciences Business Description

Other Exchanges GENF:UKWQ5:Germany
Address 6 Heddon Street, London, GBR, W1B 4BT
Genflow Biosciences PLC is a preclinical biotechnology company focused on the development of biological interventions (namely gene therapies) which are aimed at tackling the effects of aging, potentially slowing or halting the aging process and so reducing the incidence of age-related diseases and thereby increasing health span. Its flagship compound, GF-1002, is based on the delivery of a variant of the SIRT6 gene and is currently in preclinical development.